Therapy Areas
Trastuzumab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen
29 June 2022 - - Japan-based pharmaceutical company Daiichi Sankyo (TSX: 4568) and British-Swedish multinational pharmaceutical and biotechnology company AstraZeneca's (LSE: AZN) (STO: AZN) (NASDAQ: AZN) trastuzumab deruxtecan has been recommended for approval in the European Union as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received one or more prior anti-HER2-based regimens, the companies said.

Trastuzumab deruxtecan is a specifically engineered HER2 directed antibody drug conjugate being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.

The Committee for Medicinal Products for Human Use of the European Medicines Agency based its positive opinion on results from the DESTINY-Breast03 phase 3 trial, which were published in The New England Journal of Medicine. 

In the DESTINY-Breast03 trial, trastuzumab deruxtecan reduced the risk of disease progression or death by 72% versus trastuzumab emtansine (T-DM1) (hazard ratio [HR] = 0.28; 95% confidence interval [CI]: 0.22-0.37; p
Login
Username:

Password:


Related Headlines

Gilead Sciences Forges Collaboration with Morehouse School of Medicine and Xavier University of Louisiana College of Pharmacy to Address Inequities in HIV Care

Dorton, Davis Added to Sonoma Biotherapeutics B of Directors

Genexine doses first patient in phase 2 clinical trial using triple combination therapy in patients with head and neck squamous cell carcinoma

Pneumagen doses first participant in Neumifil phase two controlled human infection challenge study

BeiGene Forms Strategic Alliance with Ontada to Improve US Community Oncology Care

Enhertu Significantly Delayed Disease Progression in DESTINY-Breast02 Phase 3 Trial Versus Physician's Choice of Treatment in Patients with HER2 Positive Metastatic Breast Cancer

AstraZeneca reports Lynparza granted FDA Priority Review

GSK completes Affinivax acquisition

Inhibrx's INBRX-109 receives EMA orphan medicinal product designation to treat chondrosarcoma

Anixa Biosciences treats first patient in CAR-T therapy ovarian cancer clinical trial in collaboration with Moffitt Cancer Center

Q32 Bio and Horizon Therapeutics Forge Collaboration in Autoimmune Diseases

Monod Bio Closes USD 25m Seed Financing to Advance Biosensor Technology Platform

HiFiBiO Therapeutics Inks Clinical Trial Supply Agreement to Evaluate HFB200301 in Combination with Tislelizumab in Patients with DIS Selected Advanced Solid Tumors

EpiAxis Therapeutics and Peptilogics Enter Strategic Drug Discovery Partnership

Cure Rare Disease Receives FDA Approval to Administer First-in-Human CRISPR Therapeutic